Mar 17 2010
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results
of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination
with the chemotherapy agents paclitaxel and carboplatin as first-line
therapy in advanced non-small cell lung cancer (NSCLC).
The results showed no difference in disease response or progression-free
survival for the combination that included mapatumumab vs. the control
group, and showed that mapatumumab was well tolerated in this study. HGS
expects to present the results in full at an appropriate scientific
meeting later in 2010.
Source Human Genome Sciences